Candida albicans and Pseudomonas aeruginosa interactions: More than an opportunistic criminal association?

Medecine et Maladies Infectieuses

Volumn 43, Issue 4, 2013, Pages 146-151

  Mear J B ^a,c   Kipnis, E ^a,b   Faure, E ^a   Dessein, R ^a   Schurtz, G ^b   Faure, K ^a,b   Guery, B ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Candida albicans; Pneumonia; Pseudomonas aeruginosa; Virulence factors

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; FARNESOL; PYOCYANINE; VIRULENCE FACTOR;

ANTIBIOTIC THERAPY; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BACTERIAL VIRULENCE; BURN; CANDIDA ALBICANS; CANDIDEMIA; CAUSE OF DEATH; CRITICALLY ILL PATIENT; FUNGAL COLONIZATION; FUNGAL VIRULENCE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTENSIVE CARE UNIT; LUNG EMBOLISM; LUNG MYCOSIS; MIXED INFECTION; NONHUMAN; OPPORTUNISTIC INFECTION; ORGANISMAL INTERACTION; PATHOGENESIS; PERITONITIS; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; QUORUM SENSING; REVIEW; THRUSH;

BIOFILMS; CANDIDA ALBICANS; CANDIDIASIS; COINFECTION; HOST-PATHOGEN INTERACTIONS; HUMANS; OPPORTUNISTIC INFECTIONS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUORUM SENSING; VIRULENCE;

EID: 84878015645     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2013.02.005     Document Type: Review

References (51)

1. Morales D.K., Hogan D.A. Candida albicans interactions with bacteria in the context of human health and disease. PLoS Pathog 2010, 6:e1000886.
2. Kennedy M.J., Volz P.A. Ecology of Candida albicans gut colonization: inhibition of Candida adhesion, colonization, and dissemination from the gastrointestinal tract by bacterial antagonism. Infect Immun 1985, 49:654-663.
3. Pittet D., Monod M., Suter P.M., Frenk E., Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994, 220:751-758.
4. Jordà-Marcos R., et al. Risk factors for candidaemia in critically ill patients: a prospective surveillance study. Mycoses 2007, 50:302-310.
5. Kim J., Sudbery P. Candida albicans, a major human fungal pathogen. J Microbiol 2011, 49:171-177.
6. Sudbery P.E. Growth of Candida albicans hyphae. Nat Rev Micro 2011, 9:737-748.
7. Lo H.J., et al. Nonfilamentous C. albicans mutants are avirulent. Cell 1997, 90:939-949.
8. Chen H., Fujita M., Feng Q., Clardy J., Fink G.R. Tyrosol is a quorum-sensing molecule in Candida albicans. Proc Natl Acad Sci U S A 2004, 101:5048-5052.
9. Hornby J.M., et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001, 67:2982-2992.
10. Navarathna D.H.M.L.P., et al. Effect of farnesol on a mouse model of systemic candidiasis, determined by use of a DPP3 knockout mutant of Candida albicans. Infect Immun 2007, 75:1609-1618.
11. Ramage G., Saville S.P., Thomas D.P., López-Ribot J.L. Candida biofilms: an update. Eukaryot Cell 2005, 4:633-638.
12. El-Azizi M.A., Starks S.E., Khardori N. Interactions of Candida albicans with other Candida spp. and bacteria in the biofilms. J Appl Microbiol 2004, 96:1067-1073.
13. Lyczak J.B., Cannon C.L., Pier G.B. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect 2000, 2:1051-1060.
14. Chastre J., Fagon J.Y. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165:867-903.
15. Kipnis E., Sawa T., Wiener-Kronish J. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect 2006, 36:78-91.
16. Hauser A.R. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Micro 2009, 7:654-665.
17. Ran H., Hassett D.J., Lau G.W. Human targets of Pseudomonas aeruginosa pyocyanin. Proc Natl Acad Sci U S A 2003, 100:14315-14320.
18. Le Berre R., et al. Quorum-sensing activity and related virulence factor expression in clinically pathogenic isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2008, 14:337-343.
19. Jensen P.O., et al. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology 2007, 153:1329-1338.
20. Miller M.B., Bassler B.L. Quorum sensing in bacteria. Annu Rev Microbiol 2001, 55:165-199.
21. Pearson J.P., Feldman M., Iglewski B.H., Prince A. Pseudomonas aeruginosa cell-to-cell signaling is required for virulence in a model of acute pulmonary infection. Infect Immun 2000, 68:4331-4334.
22. Equi A., Balfour-Lynn I.M., Bush A., Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984.
23. Adair C.G., et al. Implications of endotracheal tube biofilm for ventilator-associated pneumonia. Intensive Care Med 1999, 25:1072-1076.
24. Pier G.B., Meluleni G., Neuger E. A murine model of chronic mucosal colonization by Pseudomonas aeruginosa. Infect Immun 1992, 60:4768-4776.
25. Hibbing M.E., Fuqua C., Parsek M.R., Peterson S.B. Bacterial competition: surviving and thriving in the microbial jungle. Nat Rev Micro 2010, 8:15-25.
26. Hughes W.T., Kim H.K. Mycoflora in cystic fibrosis: some ecologic aspects of Pseudomonas aeruginosa and Candida albicans. Mycopathol Mycol Appl 1973, 50:261-269.
27. Kerr J.R., et al. Pseudomonas aeruginosa pyocyanin and 1-hydroxyphenazine inhibit fungal growth. J Clin Pathol 1999, 52:385-387.
28. Morales D.K., et al. Antifungal mechanisms by which a novel Pseudomonas aeruginosa phenazine toxin kills Candida albicans in biofilms. Mol Microbiol 2010, 78:1379-1392.
29. Brand A., Barnes J.D., Mackenzie K.S., Odds F.C., Gow N.A.R. Cell wall glycans and soluble factors determine the interactions between the hyphae of Candida albicans and Pseudomonas aeruginosa. FEMS Microbiol Lett 2008, 287:48-55.
30. Bauer T.T., et al. Biofilm formation in endotracheal tubes. Association between pneumonia and the persistence of pathogens. Monaldi Arch Chest Dis 2002, 57:84-87.
31. Hogan D.A., Kolter R. Pseudomonas-Candida interactions: an ecological role for virulence factors. Science 2002, 296:2229-2232.
32. Xu X.L., et al. Bacterial peptidoglycan triggers Candida albicans hyphal growth by directly activating the adenylyl cyclase Cyr1p. Cell Host Microbe 2008, 4:28-39.
33. Hogan D.A., Vik A., Kolter R. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol 2004, 54:1212-1223.
34. McAlester G., O'Gara F., Morrissey J.P. Signal-mediated interactions between Pseudomonas aeruginosa and Candida albicans. J Med Microbiol 2008, 57:563-569.
35. Cugini C., et al. Farnesol, a common sesquiterpene, inhibits PQS production in Pseudomonas aeruginosa. Mol Microbiol 2007, 65:896-906.
36. Overhage J., Bains M., Brazas M.D., Hancock R.E.W. Swarming of Pseudomonas aeruginosa is a complex adaptation leading to increased production of virulence factors and antibiotic resistance. J Bacteriol 2008, 190:2671-2679.
37. Jabra-Rizk M.A., Meiller T.F., James C.E., Shirtliff M.E. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother 2006, 50:1463-1469.
38. Brehm-Stecher B.F., Johnson E.A. Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone. Antimicrob Agents Chemother 2003, 47:3357-3360.
39. Teplitski M., Mathesius U., Rumbaugh K.P. Perception and degradation of N-acyl homoserine lactone quorum sensing signals by mammalian and plant cells. Chem Rev 2011, 111:100-116.
40. Roux D., et al. Candida albicans impairs macrophage function and facilitates Pseudomonas aeruginosa pneumonia in rat. Crit Care Med 2009, 37:1062-1067.
41. Ader F., et al. Short term Candida albicans colonization reduces Pseudomonas aeruginosa-related lung injury and bacterial burden in a murine model. Crit Care 2011, 15:R150.
42. Evans S.E., et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol Biol 2010, 42:40-50.
43. Carlson E. Enhancement by Candida albicans of Staphylococcus aureus, Serratia marcescens, and Streptococcus faecalis in the establishment of infection in mice. Infect Immun 1983, 39:193-197.
44. Neely A.N., Law E.J., Holder I.A. Increased susceptibility to lethal Candida infections in burned mice preinfected with Pseudomonas aeruginosa or pretreated with proteolytic enzymes. Infect Immun 1986, 52:200-204.
45. Kerr J.R. Suppression of fungal growth exhibited by Pseudomonas aeruginosa. J Clin Microbiol 1994, 32:525-527.
46. Takahashi S., Uehara T., Shima M., Takasugi S., Hashimoto K., Itoh N. Septic pulmonary embolism caused by Candida albicans after treatment for urinary multidrug-resistant Pseudomonas aeruginosa. J Infect Chemother 2008, 14(6):436-438. 10.1007/s10156-008-0646-8.
47. Palabiyikoglu I., Oral M., Tulunay M. Candida colonization in mechanically ventilated patients. J Hosp Infect 2001, 47:239-242.
48. Meersseman W., et al. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med 2009, 35:1526-1531.
49. Fujitani S., Sun H.Y., Yu V.L., Weingarten J.A. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 2011, 139:909-919.
50. Azoulay E., et al. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest 2006, 129:110-117.
51. Nseir S., et al. Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study. Intensive Care Med 2007, 33:137-142.